Kestra Medical Technologies (NASDAQ:KMTS) Director Sells 4,010 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Director Elizabeth Kwo sold 4,010 shares of Kestra Medical Technologies stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $24.26, for a total value of $97,282.60. Following the sale, the director directly owned 14,116 shares in the company, valued at approximately $342,454.16. This trade represents a 22.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Performance

KMTS stock traded down $0.58 on Wednesday, reaching $25.51. The company’s stock had a trading volume of 222,727 shares, compared to its average volume of 344,534. Kestra Medical Technologies, Ltd. has a 52 week low of $17.34 and a 52 week high of $30.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.69 and a quick ratio of 4.69. The company has a market capitalization of $1.52 billion, a P/E ratio of -9.55 and a beta of 0.62. The firm has a fifty day moving average of $25.11 and a two-hundred day moving average of $22.72.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its earnings results on Monday, September 14th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.14). Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. The business had revenue of $30.97 million for the quarter. As a group, analysts predict that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on KMTS. BTIG Research reiterated a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Piper Sandler reaffirmed an “overweight” rating on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Weiss Ratings upgraded shares of Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 16th. Wall Street Zen lowered shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, September 12th. Finally, Oppenheimer began coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They issued a “market perform” rating for the company. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $28.38.

Institutional Investors Weigh In On Kestra Medical Technologies

Institutional investors and hedge funds have recently bought and sold shares of the business. Seven Grand Managers LLC bought a new position in shares of Kestra Medical Technologies during the 4th quarter valued at about $2,652,000. Eventide Asset Management LLC raised its holdings in shares of Kestra Medical Technologies by 5.4% in the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after purchasing an additional 65,288 shares in the last quarter. Sei Investments Co. lifted its stake in Kestra Medical Technologies by 22.6% during the first quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after purchasing an additional 43,753 shares during the last quarter. Summit Partners Public Asset Management LLC bought a new stake in Kestra Medical Technologies during the fourth quarter worth approximately $9,282,000. Finally, Next Century Growth Investors LLC grew its position in Kestra Medical Technologies by 154.5% in the fourth quarter. Next Century Growth Investors LLC now owns 465,845 shares of the company’s stock worth $12,354,000 after buying an additional 282,832 shares during the last quarter.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies for patients at risk of sudden cardiac arrest. The company’s primary product is the ASSURE wearable cardioverter defibrillator, a wearable system designed to continuously monitor a patient’s heart rhythm and deliver an electrical shock when a life-threatening arrhythmia is detected.

The ASSURE system is intended to provide temporary protection for patients who may be at elevated risk of sudden cardiac death but are not yet candidates for, or are awaiting, an implantable cardioverter-defibrillator.